Live Chat
Today's Hours: 8:00am - 10:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Book
    Daniel Coyle.
    Summary: "Daniel Coyle spent three years researching the question of what makes a successful group tick, visiting some of the world's most productive groups--including Pixar, Navy SEALs, Zappos, IDEO, and the San Antonio Spurs. Coyle discovered that high-performing groups relentlessly generate three key messages that enable them to excel: 1) Safety - we are connected. 2) Shared Risk - we are vulnerable together. 3) Purpose - we are part of the same story. Filled with first-hand reporting, fascinating science, compelling real-world stories, and leadership tools that can apply to businesses, schools, sports, families, and any kind of group, The Culture Code will revolutionize how you think about creating and sustaining successful groups."-- Provided by publisher.

    Contents:
    Introduction: When two plus two equals ten
    Skill 1. Build safety
    The good apples
    The billion-dollar day when nothing happened
    The Christmas truce, the one-hour experiment, and the missileers
    How to build belonging
    How to design for belonging
    Ideas for action
    Skill 2. Share vulnerability
    "Tell me what you want, and I'll help you"
    The vulnerability loop
    The super-cooperators
    How to create cooperation in small groups
    How to create cooperation with individuals
    Ideas for action
    Skill 3. Establish purpose
    Three hundred and eleven words
    The hooligans and the surgeons
    How to lead for proficiency
    How to lead for creativity
    Ideas for action
    Epilogue.
    Digital Access
    Provider
    Version
    OverDrive
    Fulltext Limited to 1 simultaneous usersSUNet ID login required
    OverDrive
    Audio Book Limited to 1 simultaneous usersSUNet ID login required
  • Article
    Myers LW, Ellison GW, Lucia M, Novom S, Holevoet M, Madden D, Sever J, Noble GR.
    J Infect Dis. 1977 Dec;136 Suppl:S546-54.
    A double-blind, placebo-controlled study was conducted to evaluate the safety and efficacy of inactivated influenza virus vaccines in patients with multiple sclerosis. The vaccine used contained 200 chick cell-agglutinating (CCA) units of influenza A/New Jersey/76 and 200 CCA units of influenza A/Victoria/75 whole viruses (Merrell-National Laboratories, Cincinnati, Ohio). The frequency of clinical relapses of multiple sclerosis was the same in the vaccine-treated (four of 33 patients) and placebo-treated (four of 33) groups. An untreated control group had a slightly higher rate of relapses (four of 22). Toxic reactions to the vaccine were not a significant problem. The efficacy of the vaccination as measured by titers of hemagglutination-inhibiting antibody was comparable to that reported for the general population. However, patients with preexisting antibody were less responsive to the vaccine than normal controls studied previously. The patients who did not respond to the vaccine tended to be older and more disabled. There were no changes in titers of antibody to rubeola or rubella virus after vaccination or in relation to change in clinical course. It is concluded that the vaccine is safe and effective in patients with multiple sclerosis.
    Digital Access Access Options